The global downstream processing market size will advance at a CAGR of 10.3% during 2021–2030, to reach $51.0 billion by 2030. The increasing adoption of biotech processes in the pharmaceutical, agricultural, and bio-services industries, the rising demand for bioproducts, the growing adoption of innovative technology in bioprocessing, the surging advancements in the fields of gene therapy and genetic engineering, and the growing commercial success of biopharmaceuticals are all driving the market growth.
The antibiotic production category, based on application, leads the industry, accounting for the largest revenue share, of around 32.6%, in 2021. This is ascribed to a broad range of applications of antibiotics for the management of a variety of illnesses. Antibiotic-resistant germs caused the death of about 700,000 individuals each year. As a result, there is a strong need for antibiotic development, which supports the market expansion.
Furthermore, as antibiotic resistance increases, so does the necessity for the production of antibodies that function against resistant bacteria. As a result, there is an increased demand for downstream processing for industrial-scale antibody synthesis. Also, it plays a critical role in the production of vaccines, antibodies, antibiotics, and hormones, such as insulin and human growth hormones. Hence, increasing antibiotic production boosts the market growth.
The chromatography systems category dominates the market revenue, with a maximum share of approximately 37.5% in 2021. Many firms provide secure and integrated systems that function well throughout the demanding stages of process development and production scale. Moreover, technological advancements have led to the creation of single-use chromatography, which is considered a dynamic innovation in the field of biopharma and is likely to make significant progress in terms of sales during the forecast period.
China leads the APAC downstream processing market, due to the high growth in the biopharmaceutical sector and the strong need for medicines and vaccines, in the country. The biopharmaceutical business is one of China's most active economic industries, characterized by constant revolution with sophisticated biopharmaceutical systems and technologies, and the increased business activities of biopharma companies in the nation. For instance, Asahi Kasei Corp., a solution provider to the biologics production industry, expanded its activities in China with the formation of Asahi Kasei Bioprocess Co. Ltd. (AKBC), in April 2021. The implementation of AKBC supports corporate expansion in China by improving order processing for faster delivery and inventory management.
Players in the market have been involved in acquisitions to remain competitive. For instance, in December 2021, Repligen acquired BioFlex Solutions of Newton, New Jersey. The acquisition expands and improves Repligen's single-use fluid management product portfolio while also simplifying its supply chain. Moreover, the addition of BioFlex Solutions expands Repligen’s system offering by incorporating additional components and assemblies.
Some of the major companies in the downstream processing market are GE Healthcare, Thermo Fisher Scientific Inc., Sartorius Stedim Biotech S.A., Danaher Corporation, Dover Corporation, Lonza Group Ltd., Ferner PLC, Repligen, and Eppendorf SE.